Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.58 |
| ▸ | CA2 | P00918 | 6/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1242368 | 0.98 | CA1 (0.56) | CA1CA2CA12CA9ALOX15 | |
| Bicarbonate SCHEMBL4899567 | 0.96 | CA1 (0.55) | CA1CA2CA12CA9ALOX15 | |
| Butanedione SCHEMBL17913120 | 0.94 | CA1 (0.53) | CA1CA2CA12CA9ALOX15 | |
| Sulfuric Acid SCHEMBL2396292 | 0.93 | CA1 (0.51) | CA1CA2CA12CA9ALOX15 | |
| Pyruvate SCHEMBL4586594 | 0.91 | CA1 (0.50) | CA1CA2CA12CA9ALOX15 | |
| SCHEMBL19152428 | 0.88 | CA1 (0.42) | CA1CA2CA12CA9ALOX15 | |
| SCHEMBL4098848 | 0.85 | CA1 (0.42) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL4586999 | 0.83 | CA12 (0.62) | CA1CA2CA12CA9ALOX15 | |
| Malic Acid SCHEMBL31238937 | 0.83 | CA12 (0.43) | CA1CA2CA12CA9ALOX15 | |
| SCHEMBL4589521 | 0.82 | NAAA (0.43) | CA1CA2CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240138438-A1 | CREATINE NUTRITIONAL SUPPLEMENT | MENTER DYLAN (US) | 2024-05-02 | — | — | US | claimed |
| US-11970435-B2 | Taste-modified creatine salts, compounds, compositions and uses thereof | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2024-04-30 | — | — | US | claimed |
| US-11865097-B2 | Creatine nutritional supplement | MENTER DYLAN (US) | 2024-01-09 | — | — | US | claimed |
| US-20230233499-A1 | CREATINE NUTRITIONAL SUPPLEMENT | MENTER DYLAN (US) | 2023-07-27 | — | — | US | claimed |
| US-11690858-B1 | Neuroprotective mixture for mitigating the harmful effects of ischemic stroke | TRICERAPRO HOLDING, LLC (US) | 2023-07-04 | — | — | US | claimed |
| US-11642327-B2 | Creatine nutritional supplement | MENTER DYLAN ROBERT (US) | 2023-05-09 | — | — | US | claimed |
| US-20230108723-A1 | Multi-Nutrient Composition | EXERKINE CORPORATION (CA) | 2023-04-06 | — | — | US | claimed |
| WO-2023055751-A1 | MIXED SOLVENT HYDROGEL SYSTEM FOR WOUND HEALING | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-04-06 | — | — | WO | claimed |
| US-11504413-B2 | Multi-nutrient composition | EXERKINE CORPORATION (CA) | 2022-11-22 | — | — | US | claimed |
| US-20220323388-A1 | CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOF | YU RUEY J (US) | 2022-10-13 | — | — | US | claimed |
| US-20060062853-A1 | Treating neuromuscular disorders with an oral formulation of creatine derivatives | MEDICAL RESEARCH INSTITUTE | 2006-03-23 | — | — | US | claimed |
| EP-1324760-A4 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | REGENTS OFTHE UNIVERSITY OF NE (US) | 2005-08-10 | — | — | EP | claimed |
| US-20050147620-A1 | Cinnamon formulation for reducing cholesterol and/or glucose levels | BOZICEVIC KARL (US) | 2005-07-07 | — | — | US | claimed |
| WO-2005039539-A1 | ORAL FORMULATION OF LIPID SOLUBLE THIAMINE, LIPOIC ACID, CREATINE DERIVATIVE, AND L-ARGININE α-KETOGLUTARATE | MEDICAL RESEARCH INSTITUTE (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050085498-A1 | Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate | NATROL, INC. | 2005-04-21 | — | — | US | claimed |
| WO-2004071406-A2 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2004-08-26 | — | — | WO | claimed |
| US-20030212130-A1 | Creatine ester anti-inflammatory compounds and formulations | NEBRASKA, UNIVERSITY OF MEDICAL CENTER | 2003-11-13 | — | — | US | claimed |
| US-20030212136-A1 | Creatine ester pronutrient compounds and formulations | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2003-11-13 | — | — | US | claimed |
| EP-1324760-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | Board of Regents of the University of Nebraska (US) | 2003-07-09 | — | — | EP | claimed |
| WO-2002022135-A1 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2002-03-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212130-A1 | Creatine ester anti-inflammatory compounds and formulations | CKMT1A; CKMT1B, CPT1B, CRAT | CA1 2415/4885CA2 901/4885CA12 2492/4885 |
| US-20050085498-A1 | Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate | SLC19A2, TKT, TTPA | CA1 3643/4885CA2 2512/4885CA12 4716/4885 |
| US-20030212136-A1 | Creatine ester pronutrient compounds and formulations | CKMT1A; CKMT1B, CPT1B, PYGM | CA1 3674/4885CA2 3567/4885CA12 3171/4885 |
| US-20060062853-A1 | Treating neuromuscular disorders with an oral formulation of creatine derivatives | TNNC1, PYGM, ATP2A3 | CA1 1790/4885CA2 443/4885CA12 2097/4885 |
| US-11970435-B2 | Taste-modified creatine salts, compounds, compositions and uses thereof | CKMT1A; CKMT1B, TAS2R16, TAS2R4 | CA1 442/4885CA2 230/4885CA12 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.